July 15, 2022: We agree that there is evidence that PET Aß imaging is a useful tool to support a diagnosis of Alzheimer’s Disease as part of a clinical trial protocol. However, there are conflicting data regarding its usefulness to determine the effectiveness of Alzheimer’s Disease treatment strategies.
Read More »Tag: CMS
High Praise, Condemnation for CMS Aduhelm Coverage Plan
Medscape Medical News, February 16, 2022: Medicare has received a key endorsement and considerable support for its plan to restrict payment for the controversial Alzheimer’s disease drug aducanumab (Aduhelm) — but also drew pleas from other groups for more generous reimbursement of the drug.
Read More »Biogen Alzheimer’s Drug Coverage Threatens Minorities’ Access
Bloomberg Law, January 13, 2022: Minority groups could have a harder time accessing Aduhelm, Biogen Inc.’s Alzheimer’s drug, under Medicare’s preliminary decision to limit coverage to patients enrolled in clinical trials, policy analysts say. But we explain that it will ensure that patients understand that the drug is experimental, with proven risks but no proven benefits.
Read More »NCHR Comments on CMS’s Proposed Decision Memo on Screening for Lung Cancer with Low Dose Computed Tomography (LDCT)
December 17, 2021. We agree that former smokers would benefit from a higher rate of LDCT screening. However, we are concerned with several major aspects of the Proposed Decision Memo’s discussion of Counseling and Shared Decision-Making.
Read More »NCHR’s Comments to CMS on the 2022 Medicare Physician Fee Schedule
September 13, 2021: We support the continued funding of telehealth services for mental health appointments, though additional data needs to be collected and patient preferences need to be taken into account.
Read More »